Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.

doi:10.1016/S2213-2600(24)00211-X

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.

The Lancet. Respiratory medicine - 1 Dec 2024

Yu Yongfeng, Guo Qisen, Zhang Yongchang, Fang Jian, Zhong Diansheng, Liu Baogang, Pan Pinhua, Lv Dongqing, Wu Lin, Zhao Yanqiu, Li Juan, Liu Zhihua, Liu Chunling, Su Haichuan, Fan Yun, Zhang Tongmei, Liu Anwen, Jin Bo, Wang Ye, Zhou Jianying, Zhang Zhihong, Ran Fengming, Song Xia, Shi Michael, Su Weiguo, Lu Shun

Abstract excerpt

BACKGROUND: Savolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Exons

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Pyrazines

Share to Treatment Outcome

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 39270695
DOI: 10.1016/S2213-2600(24)00211-X

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.PMID 39270695Read ↗

Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialSemantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.Semantic proximity Read ↗

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.